GLP-1 Bridge Program and Part D Changes Launching July 2026
Key Questions
When does the Medicare GLP-1 Bridge program start and what does it offer?
The program launches July 1, 2026, with a flat $50 copay for eligible weight-loss drugs. Strict eligibility criteria apply and coverage is limited to certain GLP-1 medications.
How long will the GLP-1 Bridge program last?
The program is scheduled to sunset after December 31, 2027. Congress has not yet extended it, creating uncertainty for beneficiaries and advisors.
What other Part D changes are occurring in 2027?
The out-of-pocket maximum rises to $2,100, the deductible increases to $615, and 10 negotiated drugs will have lower prices. CMS also issued an RFI on Part D PBM reform with a 2028 effective date.
What are common reasons for GLP-1 drug denials in Medicare?
Denials often stem from the distinction between diabetes and weight-loss indications. Prior authorization barriers remain a significant hurdle for beneficiaries.
What concerns exist about the long-term cost of the GLP-1 Bridge program?
Analysts warn of open-ended taxpayer exposure due to the absence of a spending cap. The program's future beyond 2027 remains uncertain without congressional action.
The Medicare GLP-1 Bridge program starts July 1, 2026, offering flat $50 copay for weight-loss drugs with strict eligibility. A new article highlights the sunset risk after 2027, as Congress has not extended the program, creating uncertainty for beneficiaries and advisors. Analysts warn of open-ended taxpayer exposure with no spending cap. Other Part D changes: out-of-pocket max increase to $2,100, deductible bump to $615, and 10 negotiated drugs with lower prices. A new video explains common denial reasons for weight-loss drugs. CMS also issued an RFI on Part D PBM reform under the CAA 2026, focusing on entity definitions and fair market value, with a 2028 effective date. A practical guide for beneficiaries on GLP-1 coverage details the diabetes vs weight loss distinction and prior authorization barriers.